Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
ScienceAlert reports on a phase 3 trial in The New England Journal of Medicine of retatrutide, an experimental weekly injection, in 2,339 adults with obesity but without diabetes. At 12 milligrams, average weight loss was 25 percent after 80 weeks versus 3.9 percent with placebo; knee pain and sleep apnea events also fell more. Nausea was common. Eli Lilly funded the study, which did not compare it with existing drugs.
Why it matters: Relevant to Maryland adults with obesity but without diabetes who are exploring medical weight loss, including those with knee osteoarthritis or sleep apnea, and to clinicians who refer them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to yahoo.com. October 4, 2026.